A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Imatinib (Primary) ; Ipilimumab (Primary)
  • Indications Gastrointestinal stromal tumours; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 10 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top